東阿阿膠(000423.SZ):2023年圍繞兩個關鍵詞“增長”“效率”開展相關工作
格隆匯2月20日丨東阿阿膠(000423.SZ)於2023年2月16日在投資者交流會上表示,2023年,公司圍繞兩個關鍵詞——“增長”“效率”,開展相關工作。
首先是增長。主要包括以下幾個層面,一是鎖定確定的增長,比如阿膠塊的增長、複方阿膠漿的增長、桃花姬的增長,以及阿膠粉的增長,二是發現可能的增長,例如海龍膠口服液、龜鹿二仙口服液等,還包括不同渠道、線上的增長。三是持續培育未來的增長點,做好雙輪驅動。
其次是效率。要極大提升供應鏈響應效率,提升決策和審批效率,打造高效協同組織。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.